Clinical analysis of 12 cases with myeloid sarcoma
10.3760/cma.j.cn115356-20221002-00281
- VernacularTitle:髓系肉瘤12例临床分析
- Author:
Jingjing LIANG
1
;
Juan REN
;
Linhua YANG
Author Information
1. 山西医科大学第二医院血液科，太原 030001
- Keywords:
Sarcoma, myeloid;
Immunophenotyping;
Survival analysis
- From:
Journal of Leukemia & Lymphoma
2023;32(10):600-604
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical characteristics of myeloid sarcoma (MS) and to improve the understanding of MS.Methods:The clinical manifestations, diagnosis, treatment and survival of 12 MS patients in the Second Hospital of Shanxi Medical University between January 2015 and June 2021 were retrospectively analyzed, and the survival analysis was performed by using Kaplan-Meier method.Results:All 12 patients included 8 males and 4 females, with the median age of 42 years (24-66 years). Bone (10 cases) and soft tissue (6 cases) were the most easily involved sites, followed by skin, lymph nodes and central nervous system. Immunohistochemistry results showed that MPO, CD117, Ki-67, CD34, CD99, Lys, CD43, LCA, CD68 and CD163 were positive. Molecular biology and cytogenetic tests were performed in 8 patients, including 7 cases of gene abnormalities (3 cases of ASXL1 mutation, 2 cases of JAK2 mutation, 2 cases of TET2 mutation), and 4 cases of chromosome abnormalities. Therapy regimen was predominantly the combined treatment; 5 patients received local tumor resection, 10 patients received chemotherapy, 2 patients received radiotherapy and 5 patients received hematopoietic stem cell transplantation. Finally, 3 cases lost the follow-up, and the left 9 cases were included in the survival analysis with the median follow-up time of 7 months (1-72 months); 5 cases died, and 4 cases survived.Conclusions:MS may involve multiple sites and is accompanied by other blood related diseases. The clinical diagnosis mainly depends on histopathology combined with immunophenotyping. Regular chemotherapy combined with hematopoietic stem cell transplantation is the main treatment regimen for MS.
